Bio-Thera Solutions secured European Commission marketing authorization for Usymro (BAT-2206), a biosimilar to Janssen’s Stelara (ustekinumab). The EMA's positive opinion and subsequent approval enable Bio-Thera to market the biosimilar across Europe, providing an alternative for treating conditions currently targeted by Stelara. This regulatory milestone highlights ongoing competition and biosimilar adoption efforts within immunology therapeutics.